Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TERIPARATIDE vs EUTHROID-3
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Teriparatide is a recombinant fragment of human parathyroid hormone (PTH 1-34). It acts by stimulating osteoblast activity, increasing bone formation, and improving bone microarchitecture.
EUTHROID-3 is a combination of liothyronine (T3) and levothyroxine (T4) that supplements endogenous thyroid hormone. T4 is converted to the active T3 in peripheral tissues. T3 binds to thyroid hormone receptors in the cell nucleus, modulating gene transcription and increasing metabolism, protein synthesis, and oxygen consumption.
Treatment of postmenopausal women with osteoporosis at high risk for fracture,Treatment of men with primary or hypogonadal osteoporosis at high risk for fracture,Treatment of men and women with glucocorticoid-induced osteoporosis at high risk for fracture
Hypothyroidism (thyroid hormone replacement therapy),Thyroid-stimulating hormone suppression in thyroid cancer (off-label)
20 mcg subcutaneously once daily.
Levothyroxine/liothyronine combination (EUTHROID-3): 1 tablet (50 mcg levothyroxine, 15 mcg liothyronine) orally once daily, adjusted based on TSH levels.
Terminal half-life approximately 1 hour following subcutaneous administration; clinical duration limited by rapid clearance, necessitating once-daily dosing.
L-T4: 6-7 days; L-T3: 1-2 days. Clinical context: Steady-state achieved in ~6 weeks for T4, ~8 days for T3.
Teriparatide is metabolized via non-specific proteolytic degradation in the liver and peripheral tissues. No specific cytochrome P450 enzymes are involved.
Levothyroxine (T4) is metabolized to liothyronine (T3) via deiodination in peripheral tissues (liver, kidney, etc.). Liothyronine (T3) is metabolized via deiodination and conjugation (glucuronidation and sulfation) in the liver and kidneys. Hepatic enzymes involved include deiodinases (D1, D2) and UDP-glucuronosyltransferases (UGTs).
Primarily hepatic metabolism via nonspecific proteolytic enzymes; no significant renal or biliary excretion; minimal unchanged drug in urine or feces.
Renal (approx. 20-40% as unchanged drug and metabolites), biliary/fecal (approx. 60-80% as conjugated metabolites).
Approximately 40-50% bound to plasma proteins, primarily albumin.
99.8% for L-T4 (thyroxine-binding globulin, transthyretin, albumin); 99.7% for L-T3 (same proteins, lower affinity).
Approximately 0.2-0.3 L/kg, indicating distribution largely confined to extracellular fluid and bone.
L-T4: 0.1-0.2 L/kg (mainly intravascular); L-T3: 0.4-0.6 L/kg (broader tissue distribution).
Subcutaneous: approximately 95% bioavailability.
Oral L-T4: 80-90% (fasting; reduced by food and malabsorption). Oral L-T3: 95-100% (well absorbed).
No dose adjustment required for mild to moderate renal impairment (Cr Cl >30 m L/min). Not recommended in severe renal impairment (Cr Cl ≤30 m L/min) due to lack of data.
No specific GFR-based dose adjustment required; monitor thyroid function in severe chronic kidney disease (GFR <30 m L/min/1.73 m²) as drug clearance may be reduced.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh class A or B). Not studied in severe hepatic impairment (Child-Pugh class C).
No specific adjustment for Child-Pugh class A or B; use with caution in Child-Pugh C due to reduced hepatic conversion, monitor TSH.
Not approved for use in pediatric patients; safety and efficacy not established.
Not FDA-approved for children; adult dose not suitable. For hypothyroidism in children, use levothyroxine monotherapy at 25-50 mcg/day for ages 1-3 years, 50-100 mcg/day for ages 3-10 years, and 100-150 mcg/day for ages 10-16 years, adjusted per TSH.
No dose adjustment required; clinical studies included patients >65 years with no significant differences in efficacy or safety.
Start with lower dose: 25 mcg levothyroxine/7.5 mcg liothyronine (half tablet) orally once daily, titrate slowly every 4-6 weeks based on TSH, due to increased risk of cardiac adverse effects and altered metabolism.
Increased risk of osteosarcoma in animal studies. Avoid use in patients with Paget's disease of bone, unexplained elevations of alkaline phosphatase, open epiphyses, prior radiation therapy involving the skeleton, or bone metastases.
None
Risk of osteosarcoma (see black box warning),Orthostatic hypotension may occur, especially with initial doses,Hypercalcemia may occur; monitor serum calcium,Use with caution in patients with active urolithiasis,May increase serum uric acid
Cardiac toxicity (e.g., arrhythmias, angina, myocardial infarction) due to excessive thyroid hormone levels,Thyrotoxic crisis (thyroid storm) if overdosed,Adrenal insufficiency: may precipitate acute adrenal crisis in patients with adrenal insufficiency,Delayed bone maturation in children if overtreated,Interactions with anticoagulants (increased INR), oral antidiabetic agents (hyperglycemia), and catecholamines (sympathomimetic effects)
Paget's disease of bone,Unexplained elevations of alkaline phosphatase,Open epiphyses (pediatric patients),Prior radiation therapy involving the skeleton,Bone metastases or history of skeletal malignancies,Metabolic bone diseases other than osteoporosis,Pregnancy and lactation,Hypersensitivity to teriparatide or any component
Untreated adrenal insufficiency,Thyrotoxicosis (any etiology),Acute myocardial infarction (recent),Hypersensitivity to any component
No specific food interactions. However, ensure adequate dietary calcium and vitamin D intake (e.g., dairy products, green leafy vegetables, fortified foods) to support the anabolic effect. Avoid excessive sodium, protein, and caffeine, which may increase calcium excretion. Do not take calcium supplements within 2 hours of teriparatide injection if instructed to take them separately, though generally they can be taken together.
Take on an empty stomach with water. Avoid concurrent intake with high-fiber foods, walnuts, soybean flour, cottonseed meal, or calcium/iron supplements within 4 hours of dosing as they may reduce absorption.
Insufficient human data; animal studies show skeletal abnormalities at high doses. No known risk in first trimester; avoid in second and third trimesters due to potential fetal skeletal effects.
Liothyronine (T3) and levothyroxine (T4) are endogenous thyroid hormones. Inadequate maternal thyroid hormone levels are teratogenic. At therapeutic doses, no known teratogenic risk from exogenous thyroid hormone. Fetal thyroid function develops at 10-12 weeks; prior to that, fetus depends on maternal T4. Overdose may cause fetal thyrotoxicosis. First trimester: maternal hypothyroidism increases risk of miscarriage and neurodevelopmental deficits. Second/third trimester: overtreatment may cause fetal tachycardia and growth restriction. Postpartum: adjust dose to prevent maternal hypothyroidism.
No human data; teriparatide likely excreted in milk in low amounts. M/P ratio unknown. Recommend caution or avoid breastfeeding.
Excreted in human milk in low amounts. T3 and T4 are endogenous hormones; exogenous administration results in minimal transfer. M/P ratio: not established for Euthroid-3, but for levothyroxine, M/P ratio ~0.001. Considered compatible with breastfeeding when used at recommended doses. Monitor infant for thyroid suppression (rare at maternal therapeutic doses).
No dose adjustment recommended based on pharmacokinetic changes; however, use only if potential benefit justifies risk.
Pregnancy increases T4 clearance due to increased TBG and placental deiodination. Dose may need to increase by 20-50% as early as 4-6 weeks gestation. Start with increased dose of 30-50% of prepregnancy dose. Adjust based on TSH every 4-6 weeks. Typical dose increase: 30-50% above baseline. Liothyronine component may require adjustment; monitor free T3 if using T3 therapy. Postpartum: reduce dose back to prepregnancy level.
Teriparatide is a recombinant human parathyroid hormone analog used for osteoporosis. It is the only anabolic agent that stimulates new bone formation. Administer as a subcutaneous injection in the thigh or abdomen. Rotate injection sites. Do not use in patients with Paget's disease, unexplained alkaline phosphatase elevation, prior radiation therapy to the skeleton, or bone metastases. Maximum duration of therapy is 24 months over a patient's lifetime due to an increased risk of osteosarcoma in rats. Monitor serum calcium levels at baseline and periodically; may cause transient hypercalcemia 4-6 hours after dosing. Contraindicated in hypercalcemia, pregnancy, and lactation.
Euthroid-3 is a combination of liothyronine (T3) and levothyroxine (T4) in a fixed 1:4 ratio. Monitor TSH, free T4, and free T3 levels to avoid iatrogenic hyperthyroidism. Adjust dose cautiously in elderly or cardiac patients. Use with caution in adrenal insufficiency as thyroid replacement can precipitate adrenal crisis.
Store teriparatide in the refrigerator at 2-8°C (36-46°F) and never freeze. Protect from light and do not use if the solution is cloudy, colored, or contains particles.,Inject once daily using the provided pen device. Administer at the same time each day, preferably in the morning, into the thigh or abdomen. Rotate injection sites to avoid lipodystrophy.,Sit or lie down during the first few doses if you experience dizziness or rapid heartbeat, as teriparatide may cause orthostatic hypotension. Stand up slowly.,Do not use teriparatide for more than 24 months total over your lifetime. Inform your doctor if you have Paget's disease, a history of radiation therapy, or bone cancer.,Contact your doctor if you have persistent nausea, vomiting, constipation, muscle weakness, or confusion, as these may be signs of hypercalcemia.,Take calcium and vitamin D supplements as recommended by your doctor, typically 1000 mg calcium and 800 IU vitamin D daily, to support bone formation.
Take exactly as prescribed, typically once daily on an empty stomach 30-60 minutes before breakfast.,Do not switch between different thyroid hormone products without consulting your doctor.,Report symptoms of hyperthyroidism (rapid heartbeat, chest pain, heat intolerance, excessive sweating) or hypothyroidism (fatigue, weight gain, cold intolerance).,Inform all healthcare providers you are taking this medication.,Store at room temperature away from light and moisture.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TERIPARATIDE vs EUTHROID-3, answered by our medical review team.
TERIPARATIDE is a Parathyroid Hormone Analog that works by Teriparatide is a recombinant fragment of human parathyroid hormone (PTH 1-34). It acts by stimulating osteoblast activity, increasing bone formation, and improving bone microarchitecture.. EUTHROID-3 is a Thyroid Hormone Replacement that works by EUTHROID-3 is a combination of liothyronine (T3) and levothyroxine (T4) that supplements endogenous thyroid hormone. T4 is converted to the active T3 in peripheral tissues. T3 binds to thyroid hormone receptors in the cell nucleus, modulating gene transcription and increasing metabolism, protein synthesis, and oxygen consumption.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TERIPARATIDE and EUTHROID-3 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TERIPARATIDE is: 20 mcg subcutaneously once daily.. The standard adult dose of EUTHROID-3 is: Levothyroxine/liothyronine combination (EUTHROID-3): 1 tablet (50 mcg levothyroxine, 15 mcg liothyronine) orally once daily, adjusted based on TSH levels.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TERIPARATIDE and EUTHROID-3 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TERIPARATIDE is classified as Category A/B. Insufficient human data; animal studies show skeletal abnormalities at high doses. No known risk in first trimester; avoid in second and third trimesters due to potential fetal ske. EUTHROID-3 is classified as Category C. Liothyronine (T3) and levothyroxine (T4) are endogenous thyroid hormones. Inadequate maternal thyroid hormone levels are teratogenic. At therapeutic doses, no known teratogenic ris. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.